NanoBio Starts Trial of Herpes Treatment
Posted on: Thursday, 15 February 2007, 15:01 CST
NanoBio Corporation has begun enrolling patients in its phase IIb study of its drug candidate for the topical treatment of herpes labialis, an infection that can lead to cold sores.
The phase IIb trial will be conducted at 30 sites in the US, where 1,000 potential subjects are being recruited.
"Given the remarkable safety profile of NB-001 and the clear efficacy demonstrated in our prior trial, we are now able to perform a phase IIb study with doses that are three and five times higher then previously used," stated Dr James Baker, NanoBio's chief science officer.
"NB-001 safely and effectively targets the herpes virus when applied to the skin, thus making it a promising topical treatment for herpes labialis. Its novel mechanism of action leaves little risk of drug resistance, which is a concern with the systemic anti-viral therapies used to treat this disease. These attributes may eventually allow NB-001 to be sold without a prescription."
In 2005, NanoBio completed a phase II study of NB-001 for the treatment of herpes labialis. When compared to a placebo, a substantially higher proportion of subjects receiving NB-001 healed within three days or four days. Also, the time it took for sores to heal in NB-001-treated subjects was shortened by over a day.
Source: Datamonitor
Related Articles
- Glycotex Initiates Enrollment in Phase IIb Study of Topical Wound Healing Gel
- Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years at Key Fracture Sites in Phase IIB Study
- XTL Completes Patient Randomization in Phase IIb Study of Diabetic Pain Drug
- InteKrin Initiates Phase IIb Study in Type 2 Diabetes
- Protherics Initiates Phase IIb Study in Oesophageal Cancer
- Merck's Investigational CETP-Inhibitor, MK-0859 (Anacetrapib), Produced Positive Effects on Lipids With No Observed Blood Pressure Changes in Phase IIb Study
- Increased Bone Mineral Density Seen in Phase IIB Study With Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
- Preliminary Phase IIb Study Data Demonstrate Rylomine(TM) Significantly Reduces Postsurgical Orthopedic Pain
- Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity in Treatment-Experienced HIV Patients Failing Current Treatment Regimen; Findings Presented at the 3rd International AIDS Society Conference
- Enzo Biochem Alequel Clinical Trial Results Highlighted at Digestive Disease Week Conference Press Meeting Today; Research Team to Report on Phase IIb Study of Crohn's Disease Treatment
 |
 |
User Comments (0)
RSS Feeds